BioMarin reports Factor VIII activity from Phase I/II of hemophilia A gene therapy

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported additional Phase I/II data on Factor VIII activity levels for its gene therapy to treat hemophilia A. Data were presented at the American Society of

Read the full 309 word article

User Sign In